Psoriasis and Hypertrophic cardiomyopathy

Summary:

Hypertrophic cardiomyopathy is found among people with Psoriasis, especially for people who are female, 50-59 old.

The study analyzes which people have Hypertrophic cardiomyopathy with Psoriasis. It is created by eHealthMe based on reports of 20 people who have Psoriasis from the Food and Drug Administration (FDA), and is updated regularly. You can use the study as a second opinion to make health care decisions.

What is Psoriasis?

Psoriasis (immune-mediated disease that affects the skin) is found to be associated with 1,477 drugs and 1,694 conditions by eHealthMe. Check the latest studies of Psoriasis.

What is Hypertrophic cardiomyopathy?

Hypertrophic cardiomyopathy (a condition in which the heart muscle becomes abnormally thick) is found to be associated with 265 drugs and 937 conditions by eHealthMe. Check the latest studies of Hypertrophic cardiomyopathy.

On Jul, 12, 2026

20 people who have Psoriasis and Hypertrophic Cardiomyopathy are studied.

Would you have Hypertrophic cardiomyopathy when you have Psoriasis?

Gender of people who have Psoriasis and experienced Hypertrophic Cardiomyopathy *:

female: 60 %
male: 40 %

Age of people who have Psoriasis and experienced Hypertrophic Cardiomyopathy *:

Common co-existing conditions for these people *:

Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 2 people, 10.00%
Ankylosing Spondylitis (type of arthritis affecting the spine): 2 people, 10.00%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 1 person, 5.00%

Common drugs taken by these people *:

Common symptoms for these people *:

Fatigue (feeling of tiredness): 3 people, 15.00%
Ventricular Tachycardia (rapid heartbeat that originates in one of the lower chambers (the ventricles) of the heart): 2 people, 10.00%
Aneurysm (enlargement of an artery caused by a weakening of the artery wall): 2 people, 10.00%
Arrhythmias (irregular heartbeat): 2 people, 10.00%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 2 people, 10.00%
Atherosclerosis (disorder of the arteries): 2 people, 10.00%
Hypogammaglobulinaemia (an abnormally low concentration of gamma globulin in the blood and increased risk of infection): 2 people, 10.00%
Peripheral Ischaemia (impaired circulation to an extremity): 2 people, 10.00%
Concomitant Disease Aggravated (advanced due to some of accompanying): 1 person, 5.00%
Aortic Dilatation: 1 person, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take medications and have Hypertrophic cardiomyopathy?

- Check whether Hypertrophic cardiomyopathy is associated with a drug or a condition

Related publications that referenced our studies

Mohagheghi MA, Omranipur R, Ensani F, Ghannadan A, Shahriaran S, Samiee F, Sedighi Z, "A Case of Advanced Unicentric Retroperitoneal Castleman's Disease, Associated With Psoriasis", Acta Medica Iranica, 2017 May .
Chiriac A, Brzezinski P, Stolnicu S, Podoleanu C, Moldovan C, Molnar C, Taranu T, "Eosinophilia–A rare possible adverse reaction during anti-tumor necrosis factor-alpha therapy for psoriasis", Journal of Dermatological Treatment, 2016 Mar .
Kim DJ, Lee SC, Park GS, Kim GJ, Hwang WT, Lee CS, Lee MH, Hahn DH, Koh HC, "Amiodarone Induced Multiorgan Toxicity in a Patient of Hypertrophic Cardiomyopathy With Atrial Fibrillation", Journal of the Korean Geriatrics Society, 2013 Dec .
Malisiewicz B, Murer C, Schmid JP, French LE, Schmid-Grendelmeier P, Navarini AA, "Eosinophilia during psoriasis treatment with TNF antagonists", Dermatology, 2013 Jan .
Mohagheghi MA, Omranipur R, Ensani F, Ghannadan A, Shahriaran S, Samiee F, Sedighi Z, "A Case of Advanced Unicentric Retroperitoneal Castleman's Disease, Associated With Psoriasis", Acta Medica Iranica, 2017 May .
Chiriac A, Brzezinski P, Stolnicu S, Podoleanu C, Moldovan C, Molnar C, Taranu T, "Eosinophilia–A rare possible adverse reaction during anti-tumor necrosis factor-alpha therapy for psoriasis", Journal of Dermatological Treatment, 2016 Mar .
Kim DJ, Lee SC, Park GS, Kim GJ, Hwang WT, Lee CS, Lee MH, Hahn DH, Koh HC, "Amiodarone Induced Multiorgan Toxicity in a Patient of Hypertrophic Cardiomyopathy With Atrial Fibrillation", Journal of the Korean Geriatrics Society, 2013 Dec .
Malisiewicz B, Murer C, Schmid JP, French LE, Schmid-Grendelmeier P, Navarini AA, "Eosinophilia during psoriasis treatment with TNF antagonists", Dermatology, 2013 Jan .

Related studies:

How the study uses the data?

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

The study is based on Hypertrophic cardiomyopathy and Psoriasis, and their synonyms.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.